Compare LOMA & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOMA | OPK |
|---|---|---|
| Founded | 1926 | 2006 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2017 | 2011 |
| Metric | LOMA | OPK |
|---|---|---|
| Price | $10.16 | $1.59 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $15.00 | $1.60 |
| AVG Volume (30 Days) | 397.7K | ★ 2.6M |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $606,879,000.00 |
| Revenue This Year | $27.53 | N/A |
| Revenue Next Year | N/A | $4.24 |
| P/E Ratio | $187.97 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.04 | $0.98 |
| 52 Week High | $13.20 | $1.73 |
| Indicator | LOMA | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 50.16 | 60.43 |
| Support Level | $9.57 | $1.12 |
| Resistance Level | $12.10 | $1.73 |
| Average True Range (ATR) | 0.35 | 0.07 |
| MACD | 0.14 | 0.01 |
| Stochastic Oscillator | 74.67 | 60.81 |
Loma Negra Cia Industria Argentina SA is a cement producer in Argentina. The Group is engaged in the production and distribution of cement, masonry cement, concrete, limestone, and aggregates, operates a railway concession to provide transportation services, and is also engaged in the industrial waste recycling business. The company operates in five segments: Cement, masonry cement, and lime; Concrete; Rail services; Aggregates; and Others. The majority of its revenue derives from Cement, masonry cement, and lime segments.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.